Jihui Du

Dr. Jihui Du


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2013 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JDJihui Du
Jihui Du
RRRose-Anne Romano
Rose-Anne Romano
HSHan Si
Han Si
AMAustin Mattox
Austin Mattox
YBYansong Bian
Yansong Bian
Zhong ChenZhong Chen
Zhong Chen

12 June 2023 in Genes & Genomics
Verified
Journal Article
Open access
PDF file
HZHekai Zhou
Hekai Zhou
HLHoucong Liu
Houcong Liu
JLJun Li
Jun Li
JWJidong Wang
Jidong Wang
XFXiaohong Fu
Xiaohong Fu
JDJihui Du
Jihui Du
Background: Several studies have demonstrated that circulating tumor DNA (ctDNA) can be used to predict the postoperative recurrence of several cancers. However, there are few studies on the use of ctDNA as a prognosis tool for gastric cancer (GC) patients. Objective: This study aims to determine whether ctDNA could be used as a prognostic biomarker in GC patients through multigene-panel sequencing. Methods: Using next-generation sequencing (NGS) Multigene Panels, the mutational signatures associated with the prognosis of GC patients were identified. We calculated the survival probability with Kaplan–Meier and used the Log-rank test to compare survival curves between ctDNA-positive and ctDNA-negative groups. Potential application of radiology combined with tumor plasma biomarker analysis of ctDNA in GC patients was carried out. Results: Disease progression is more likely in ctDNA-positive patients as characterized clinically by a generally higher T stage and a poorer therapeutic response (P < 0.05). ctDNA-positive patients also had worse overall-survival (OS: P = 0.203) and progression-free survival (PFS: P = 0.037). The combined analysis of ctDNA, radiological, and serum biomarkers in four patients indicated that ctDNA monitoring can be a good complement to radiological and plasma tumor markers for GC patients. Kaplan–Meier analysis using a cohort of GC patients in the TCGA database showed that patients with CBLB mutations had shorter OS and PFS than wild-type patients (OS: P = 0.0036; PFS: P = 0.0027). Conclusions: This study confirmed the utility and feasibility of ctDNA in the prognosis monitoring of gastric cancer.

11 August 2025 in Scientific Reports
Verified
Journal Article
Open access
HLHoucong Liu
Houcong Liu
LHLoren Hansen
Loren Hansen
CSChangpu Song
Changpu Song
HLHaijiu Lin
Haijiu Lin
DCDan Chen
Dan Chen
JDJihui Du
Jihui Du
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced adenoma (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in publicly available RNA-seq tissue datasets. Each gene was ranked based on observed differential expression across the majority of tumors as well as the level of expression in tumor tissue. Those genes with strong differential expression across the majority of tumors that were also highly expressed would have a higher ranking. The top 20 genes as ranked in the bioinformatic analysis of tumor and normal colon tissue gene expression were then tested on 114 clinical stool samples (CRC N = 33, AA N = 28, Controls N = 53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.

2 December 2025 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
YZYixin Zhang
Yixin Zhang
MLManping Lu
Manping Lu
JOJieqing Ouyang
Jieqing Ouyang
LLLin Liang
Lin Liang
FLFan Li
Fan Li
JDJihui Du
Jihui Du

5 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
XWXiu Wang
Xiu Wang
YHYongshen He
Yongshen He
YHYu Huang
Yu Huang
HGHui Gong
Hui Gong
LWLei Wang
Lei Wang
JDJihui Du
Jihui Du
Background: The microRNA (miRNA) miRNA-92a has been implicated in colorectal cancer (CRC) pathology. Methods: Here, we examined miRNA-92a involvement in CRC-associated angiogenesis, including examining a mechanism by which miRNA-92a may exert such effects. MiRNA-92a expression in 25 clinical CRC samples and in HT29, SW620, SW480 and HCT116 CRC cells was detected with quantitative real-time polymerase chain reaction (qRT-PCR). Blood microvessels were labeled by immunohistochemistry (IHC) with an anti-CD31 antibody. MiR-92a mimic or inhibitor were transfected into HCT116 and SW620 cells to up- and down-regulate miRNA-92a expression, respectively. The effects of altering miRNA-92a expression levels on HUVEC (human umbilical vein endothelial cell) tubule formation and PTEN protein expression were measured. Results: MiRNA-92a was more highly expressed in CRC tissues and cell lines than in matched adjacent tissues (p <0.01) and normal epithelial cells (p <0.05), respectively. Microvessel density (MVD) was elevated in CRC tissues relative to adjacent tissues (p <0.01), and miRNA-92a levels correlated with MVDs in CRC tissues (Pearson coefficient r = 0.580, p = 0.01). The cells culture supernatant of CRC cell with miRNA-92a overexpression (or suppression) can promoted (or reduced) the formation of HUVEC tubules (P <0.05). Elevated miRNA-92a expression was associated with reduced PTEN expression in CRC cells (p <0.01). Conclusion: Modulation of miR-92a, which is highly expressed in CRC cells and tissues, is associated directly with differences in CRC angiogenesis. MiR-92a could promote tumor angiogenesis in CRC by inhibiting the expression of PTEN.

18 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HLHoucong Liu
Houcong Liu
LHLoren Hansen
Loren Hansen
CSChangpu Song
Changpu Song
HLHaijiu Lin
Haijiu Lin
DCDan Chen
Dan Chen
JDJihui Du
Jihui Du
Messenger RNA (mRNA) stool based biomarkers represent a promising approach for the diagnosis of colorectal cancer (CRC) and advanced precancerous lesions (AA). But it is unclear which mRNA biomarkers have the most clinical utility. This study aims to partially fill this gap by performing an analysis which first ranks genes based on their expression profile in RNA-seq tissue datasets. The diagnostic performance of the top 20 ranked genes was then tested using 113 clinical samples (CRC N=33, AA N=28, Controls N=53). Fourteen of the genes had significant differential expression in the stool of CRC patients compared to controls (false discovery rate or FDR < 0.05). The Pearson correlation coefficient between tissue and stool expression was 0.57 (p-value = 0.007). The combined performance of the 20 genes in clinical stool samples had an area under the receiver operator curve (AUC) of 0.94 for CRC detection (sensitivity 75.5%, specificity 95%) and an AUC of 0.83 (sensitivity 55.8%, specificity 92.6%) for AA detection. The ability to use existing public transcriptomic datasets to identify promising candidate genes can substantially reduce the cost and effort required to screen for clinically useful mRNA biomarkers.